Fiorella Pepi
University of Siena
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fiorella Pepi.
American Journal of Clinical Oncology | 1998
Carmine Santomaggio; Enrico Tucci; Michela Rinaldini; Renato Algeri; Roberto Righi; Fiorella Pepi; Paolo Ghezzi; Antonio Andrei; Antonio Bellezza
The aim of this study was to identify a chemotherapy combination that would be active and well tolerated for palliative treatment of advanced non-small-cell lung cancer (NSCLC). From February 1992 to December 1994, a total of 77 patients affected by stage-IIIB and stage-IV NSCLC were treated with carboplatin 350 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8 of each cycle, with cycles repeated every 28 days. All patients were evaluable for response and toxicity. A total of 24 patients showed a partial response (31% response rate; 95% CI = 21-41%). The median duration of overall survival was 41 weeks (95% CI = 31-51), and the median time to disease progression was 34 weeks (95% CI = 25-43). The treatment was well tolerated: no grade-4 toxicity was observed. The carboplatin-vinorelbine combination deserves to considered as a valid alternative to regimens that include cisplatin for palliative treatment of advanced NSCLC.
Tumori | 1992
Luigi Pirtoli; Mirco Bindi; Antonio Bellezza; Fiorella Pepi; Enrico Tucci
The use of a reduced number of large-sized fractions in radiotherapy (hypofractionation) is usually associated with poor therapeutic results and severe adverse effects, in accord with radiobiologic concepts. However by some authors unresectable lung cancer patients have been treated with hypofractionated radiotherapy with the main aim of « convenience ». Result and damage rates are reported to be comparable to those of conventional treatment. In our experience, based on palliative irradiation of 86 advanced-stage, nonmicrocytoma patients, objective remission rates, subjective and performance status improvement, and survival overall were as poor as could be expected in this kind of presentation, with no striking impact of this treatment modality. Severe adverse effects were shown by a large proportion of cases involving skin and soft tissues of the chest wall (40 %) and lungs (55.5 %). The incidence of severe damage was in agreement with BED (biologic effective dose) values, differently from other experiences of radiotherapeutic management of advanced lung cancer with large fractions.
Tumori | 1988
Enrico Tucci; Renato Algeri; Alfredo Guarnieri; Fiorella Pepi; Lidia Sapio; Giorgio Bastreghi; Luigi Pirtoli
Twenty-nine advanced breast cancer patients, considered unable to tolerate conventional cytotoxic chemotherapy, were treated with a weekly schedule of epirubicin (15 mg/m2 i.v.). All patients were fully evaluable. A remission of 34.5 % was observed (2 CR; 8 PR), with a median duration of response of 9 months (range, 3–24 months). Side effects were mild, and on the whole the toxicity was negligible. This regimen showed a favorable therapeutic ratio in our series and seems active and well tolerated even in elderly and/or poor performance status patients.
Acta Oncologica | 1993
Luigi Pirtoli; Antonio Bellezza; Fiorella Pepi; Enrico Tucci; Monica Crociani; Crastolla Am; Mersedeh Farzad; Mirco Bindi
Results of large prospective trials, often based on selected series and optimal treatment techniques, indicate that breast conserving therapy is appropriate for most patients with early breast cancer. Questions remain regarding the therapeutic outcome in common practice. We report on a series of 206 consecutive, unselected patients treated with current radiotherapy procedures. The Kaplan-Meier evaluation showed 5- and 8-year survival rates (93%, 91%), distant disease-free survival rates (87%, 85%) and local relapse-free survival rates (90%, 88%) that were comparable to those of the conservative arms in reported randomised trials and to the data from retrospective studies reported by authoritative institutions. However, subanalysis according to prognostic factors such as menopausal status, age and axillary nodal status was of limited value, due to the small number of cases.
Tumori | 1989
Luigi Pirtoli; Enrico Tucci; Fiorella Pepi; Lucio Sebaste; Mirco Bindi; Isaia Sensini; Amos Piccini
Stage III and IV head and neck cancer patients usually achieve poor therapeutic results after radiotherapy. The search for more effective treatment modalities is justified, provided that tolerance is not lower than that of the usual radiation therapy schedules. Chemotherapy has been shown to be effective, and cisplatinum and bleomycin based treatments are reported to result in objective remissions in a substantial proportion of cases. There is also experimental evidence of a radiosensitizing activity of cisplatinum. Thirty-five locally advanced head and neck cancer patients were given combined chemo-radiotherapeutic treatment consisting of a cisplatinum and bleomycin induction followed by a standard radiotherapy course integrated with weekly administrations of cisplatinum. Before radiotherapy, an overall 48.5 % objective remission rate was achieved, that rose to 85.8 % after completion of the entire treatment, with a 31.5 % complete response rate. Incidence and severity of radiation mucositis seem not to be increased, and systemic toxicity is very low, with the adopted drug administration schedule. Overall results do not show any obvious superiority over those of radiotherapy alone.
Virchows Archiv | 1999
Clelia Miracco; Lorella Laurini; Rosa Santopietro; Maria Margherita De Santi; Carlo Sassi; Eugenio Neri; Fiorella Pepi; Pietro Luzi
Radiologia Medica | 2004
Giovanni Rubino; Palmino Sacco; Alfonso Cerase; Luca Volterrani; Lucio Sebaste; Fiorella Pepi; Luigi Pirtoli
Radiologia Medica | 1995
Luigi Pirtoli; Antonio Bellezza; Enrico Tucci; Fiorella Pepi; Crastolla Am; Farzad M; Bindi M; Lucio Sebaste
Radiologia Medica | 1998
Luigi Pirtoli; Enrico Tucci; Antonio Bellezza; Luca Volterrani; Tommaso Carfagno; Crastolla Am; Fiorella Pepi; Lucio Sebaste
European Journal of Cancer | 1998
Alessandro Neri; Alfredo Guarnieri; Enrico Tucci; Fiorella Pepi; Bruno Mazzocchi; Renato Algeri